Combination therapeutics have resulted in more positive, although modest, effects [42].It is important to note, however, that all clinical trials regarding Src inhibitors in breast cancer have been conducted in unselected patient populations and the main readout for effectiveness has been tumor size and growth, not invasion. Here, SRC is linked to breast carcinoma.